EUVIMEDEUVIMED entdecken
Crossref

MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy

Jacob F Oyeniyi, Joseph S Lee, Chen Shen, Bailey A Loving, Sirisha R Nandalur, Andrew B Thompson, Kiran R Nandalur, Zachary A Seymour, Evelyn L Sebastian, Amy Limbacher, Alvaro Martinez, Daniel J Krauss

Brachytherapy · 2026

DOI: 10.1016/j.brachy.2025.10.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Jacob F Oyeniyi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI. Hauptthemen laut MEDLINE: Brachytherapy, Prostatic Neoplasms, Magnetic Resonance Imaging. Die Arbeit nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To identify MRI features associated with treatment failure in intermediate-risk prostate cancer patients treated with HDR brachytherapy monotherapy. METHODS: We analyzed 115 men with intermediate-risk prostate cancer who underwent definitive HDR brachytherapy as monotherapy and had pretreatment MRI within 6 months. MRI features assessed included lesion size, focality, location, capsular contact (yes vs. no, with no gross extracapsular extension), length of capsular contact, and PIRADS score. Univariable and multivariate logistic regression analyses were performed to identify MRI features associated with treatment failure, defined as biochemical recurrence and/or local recurrence. RESULTS: The median age was 64 years, and median pretreatment PSA 5.95 ng/mL; 49 patients had favorable and 66 had unfavorable intermediate-risk disease. At 47 months median follow-up, 19 patients (16.5%) experienced treatment failure. MRI features associated with treatment failure on UVA included lesion size (OR: 3.9, CI: 1.8-8.8, p < 0.001), multifocality (OR: 2.9, CI: 1.0-7.9, p = 0.043), capsular contact (OR: 64.3, CI: 8.1-510.0, p < 0.001), capsular contact length ≥1 cm (OR: 5.0, CI: 1.6-15.7, p = 0.006), and PIRADS 5 (OR: 16.7, CI: 2.7-324.8, p = 0.011). On MVA, only capsular contact remained significant (OR: 57.2, CI: 9.5-106.2, p < 0.001). In patients with capsular contact (n = 39), ADT significantly reduced treatment failure (OR: 0.101, CI: 0.002-0.912, p = 0.023). CONCLUSION: Capsular contact on MRI is a strong independent predictor of treatment failure in intermediate-risk prostate cancer patients undergoing HDR brachytherapy as monotherapy. The addition of ADT significantly decreased the odds of treatment failure in these patients. These findings highlight the value of MRI-based risk stratification and suggest that treatment intensification options such as ADT could be considered to optimize treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapyProstatic NeoplasmsMagnetic Resonance ImagingHumansMaleMiddle AgedTreatment FailureAgedRadiotherapy DosageRetrospective Studies

Stichwörter der Autor:innen

ADTCapsular ContactExtra Capsular ExtensionHDR brachytherapyIntermediate risk prostate cancerMRI

Autor:innen und Institutionen

  • Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI.
  • Department of Radiation Oncology, Corewell Health Beaumont Hospital, Troy, MI.
  • Department of Radiology, Corewell Health William Beaumont University Hospital, Royal Oak, MI.
  • Department of Radiation Oncology, Corewell Health Dearborn, Dearborn, MI.
  • Department of Radiation Oncology, Michigan Healthcare Professionals (MHP), Farmington Hills, MI.
  • Department of Radiation Oncology, Corewell Health William Beaumont University Hospital, Royal Oak, MI. Electronic address: daniel.krauss@beaumont.edu.

Zitieren

APA

Oyeniyi, J. F., Lee, J. S., Shen, C., Loving, B. A., Nandalur, S. R., Thompson, A. B., Nandalur, K. R., Seymour, Z. A., Sebastian, E. L., Limbacher, A., Martinez, A., & Krauss, D. J. (2026). MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.10.012

Vancouver

Oyeniyi JF, Lee JS, Shen C, Loving BA, Nandalur SR, Thompson AB, et al. MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.10.012

BibTeX
@article{Oyeniyi2026,
  author = {Oyeniyi, Jacob F and Lee, Joseph S and Shen, Chen and Loving, Bailey A and Nandalur, Sirisha R and Thompson, Andrew B and Nandalur, Kiran R and Seymour, Zachary A and Sebastian, Evelyn L and Limbacher, Amy and Martinez, Alvaro and Krauss, Daniel J},
  title = {MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy},
  journal = {Brachytherapy},
  year = {2026},
  doi = {10.1016/j.brachy.2025.10.012}
}
Kostenlos starten →